The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index; none of the 65 sources its claims cite is checked for support yet.
Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase
Open accessAbstract
Two closely related glycosyltransferases are responsible for the final step of the biosynthesis of ABO(H) human blood group A and B antigens. The two enzymes differ by only four amino acid residues, which determine whether the enzymes transfer GalNAc from UDP-GalNAc or Gal from UDP-Gal to the H-antigen acceptor. The enzymes belong to the class of GT-A folded enzymes, grouped as GT6 in the CAZy database, and are characterized by a single domain with a metal dependent retaining reaction mechanism. However, the exact role of the four amino acid residues in the specificity of the enzymes is still unresolved. In this study, we report the first structural information of a dual specificity cis-AB blood group glycosyltransferase in complex with a synthetic UDP-GalNAc derivative. Interestingly, the GalNAc moiety adopts an unusual yet catalytically productive conformation in the binding pocket, which is different from the "tucked under" conformation previously observed for the UDP-Gal donor. In addition, we show that this UDP-GalNAc derivative in complex with the H-antigen acceptor provokes the same unusual binding pocket closure as seen for the corresponding UDP-Gal derivative. Despite this, the two derivatives show vastly different kinetic properties. Our results provide a important structural insight into the donor substrate specificity and utilization in blood group biosynthesis, which can very likely be exploited for the development of new glycosyltransferase inhibitors and probes.
Overview
CoChat Summary
TL;DR
The study reports the first crystal structures of the dual-specificity cis-AB blood group glycosyltransferase AAGlyB bound to a synthetic UDP-GalNAc derivative, revealing a non-canonical, catalytically productive GalNAc conformation. Combined with kinetics, the structures suggest that residues Gly266 and Ala268 enable AAGlyB to use both UDP-Gal and UDP-GalNAc and help explain donor specificity in blood group GTs.
Key findings
- The AAGlyB–3 structure shows the GalNAc moiety in an unusual conformation distinct from the canonical “tucked under” conformation seen with UDP-Gal, 1, or 2; O4′ hydrogen-bonds to Glu303 and His233, while O3′ hydrogen-bonds to the backbone of Gly267 and Ala268, with waters bridging to His301, Ser185, and Asp211.
- In the AAGlyB–3–HAA complex, binding of 3 and HAA triggers the same alternative C-terminal closed conformation previously seen in AAGlyB–1–HAA, with the HAA–His348 hydrogen bond disrupted; the sugar moiety is not seen in either complex.
- Compound 3 has a Km similar to that of 1 but is turned over about 25-fold faster; overall 3 resembles its parent UDP-GalNAc, with a Km about 3-fold lower and similar kcat and acceptor Km. AAGlyB hydrolyzes UDP-GalNAc at a rate ∼30 times higher than UDP-Gal, and 3 competes with UDP-Gal binding with a Ki in the same range as its Km.
- The specificity model proposes that Ala268 and Gly266 permit the alternative productive GalNAc conformation in AAGlyB, whereas GTB residues Met266 and Ala268 clash with both GalNAc conformations; GTA residues Leu266 and Gly268 could accommodate GalNAc in the tucked under conformation. Forssman synthetase has equivalent residues Gly and Ala as in AAGlyB.
Methods
- Compound 3 was synthesized by Suzuki–Miyaura cross-coupling of 5-iodo-UDP-GalNAc 4 with 5-formyl-2-thiopheneboronic acid, giving the target in 76% yield.
- Enzyme kinetics used capillary electrophoresis with a TMR-labeled HAA acceptor for Km and kcat of 3, a radiochemical SepPak assay for Ki, a Dowex hydrolysis assay, and 1H NMR to follow hydrolysis stereochemistry.
- Crystallography: AAGlyB–3 and AAGlyB–3–HAA structures were solved by molecular replacement using wild-type GTB (PDB 2RIT); both belong to space group P21212 with two molecules per asymmetric unit, refining to 1.75 Å and 1.65 Å with final Rfree values of 18.43% and 19.4%, respectively.
Limitations
- The paper states it cannot rule out a tucked under conformation of the GalNAc in wild-type GTA; the AAGlyB–3 structure provides information on residues 266 and 268 rather than directly resolving wild-type GTA donor binding.
- In AAGlyB–3, the GalNAc moiety has ∼60% occupancy, electron density suggests possible glycosidic bond cleavage, and the quality of the density did not justify modeling a glycal intermediate; chain A also showed hints of two GalNAc conformations that could not be modeled.
- The Ki assay does not differentiate between inhibitor and substrate behavior of 3 because the GalNAc moiety is not radiolabeled, and in the AAGlyB–3–HAA complex the sugar moiety is not seen, limiting direct comparison of donor sugar recognition in that ternary structure.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
0 Valid · 0 Not valid · 27 Not checked · 84 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As previously seen for 1, compound 3 competes for binding with a Ki value, which is in the same range as Km for 3.”
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A check of a cited source is scheduled, or we don’t hold its full text yet; the claim is checked once it runs.
In the paper
“Interestingly, the AAGlyB-3 structure shows the GalNAc ring in a conformation clearly different from the canonical tucked under conformation we have seen in previous blood group enzyme structures with UDP-Gal, 1, or 2 and which is the conformation generally adopted by both UDP-Gal and UDP-GalNAc at a GT binding site (Fig. 3) (7, 12, 15–18, 20, 22–24).”
- Also stated in: § Discussion · plain
“Intriguingly, this structure adopts a conformation different from the canonical tucked under conformation.”
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Results
What the sources say
- Not checked yetcites [7] Pesnot, 2010, Structural and mechanistic basis for a new mode of glycosyltransferase inhibition, Nat. Chem. Biol source
A check is scheduled.
- Not checked yetcites [12] Jørgensen, 2013, Base-modified donor analogues reveal novel dynamic features of a glycosyltransferase, J. Biol. Chem source
A check is scheduled.
- Not checked yetcites [15] Alfaro, 2008, ABO(H) blood group A and B glycosyltransferases recognize substrate via specific conformational changes, J. Biol. Chem source
A check is scheduled.
- Not checked yetcites [16] Persson, 2001, Crystal structure of the retaining galactosyltransferase LgtC from Neisseria meningitidis in complex with donor and acceptor sugar analogs, Nat. Struct. Biol source
A check is scheduled.
- Not checked yetcites [17] Pruitt, 2012, Structural determinants of Clostridium difficile toxin A glucosyltransferase activity, J. Biol. Chem source
A check is scheduled.
- Not checked yetcites [18] Ramakrishnan, 2002, Crystal structure of β1,4-galactosyltransferase complex with UDP-Gal reveals an oligosaccharide acceptor binding site, J. Mol. Biol source
A check is scheduled.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“AAGlyB catalyzes the hydrolysis of UDP-GalNAc with a rate that is ∼30 times higher than for UDP-Gal (Table 2).”
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, a water-soluble catalyst was used to successfully cross-couple the complete sugar nucleotide 4 with 5-formyl-2-thiopheneboronic acid to give the target 76% yield of UDP-GalNAc derivative 3.”
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Also, a difference electron density map of the AAGlyB-3 structure indicates that there are two slightly different positions of Asp213 in the DXD motif and the UDP phosphates (not shown).”
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Results
hedgedSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
60 more claims
Create a free account to see all 111 claims and to verify the 65 references still open.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 19
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Discussion
“In GTB, residues 266 and 268 are an alanine and methionine, respectively”
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Introduction
“GTB has residues Gly176, Ser235, Met266, and Ala268 at the corresponding positions”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Experimental Procedures > Data Collection, Reduction, and Structure Solution
“X-ray diffraction data were collected to 1.9-Å resolution on the AAGlyB-3 complex”
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Results
“The data diffracted to a maximum resolution of 1.75 and 1.65 Å with final Rfree values of 18.43 and 19.4% for AAGlyB-3 and AAGlyB-3-HAA, respectively.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Results
“O3′ forms hydrogen bonds to the backbone of Gly267 and Ala268”
§ Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase* > Results
“| O3 | Gly267 O | Gly267 O | Ala268 N | 3.1/3.1/3.2 | O4 | Glu303 Oδ2 | 2.5 |”
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
Kabsch, W. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889893005588 · Cited by 3,578
Glycosyltransferases: Structures, Functions, and Mechanisms
Lairson, L. L., Henrissat, B., Davies, G. J., & Withers, S. G. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.061005.092322 · Cited by 2,079
Likelihood-enhanced fast translation functions
McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., & Read, R. J. (2005) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905001617 · Cited by 1,639
Molecular genetic basis of the histo-blood group ABO system
Yamamoto, F.-I., Clausen, H., White, T., Marken, J., & Hakomori, S.-I. (1990) · Nature · doi:10.1038/345229a0 · Cited by 1,181
Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome
Rillahan, C. D., Antonopoulos, A., Lefort, C. T., Sonon, R., Azadi, P., Ley, K., Dell, A., Haslam, S. M., & Paulson, J. C. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.999 · Cited by 447
Research works printed but not linked: 1
- Weadge, 2008, Chemistry of Glycosyltransferases, Vol. 2, 198
Cited by
Emerging structural insights into glycosyltransferase-mediated synthesis of glycans
Moremen, K. W., & Haltiwanger, R. S. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0350-2 · Cited by 209
Sobhanifar, S., Worrall, L. J., King, D. T., Wasney, G. A., Baumann, L., Gale, R. T., Nosella, M. L., Brown, E. D., Withers, S. G., & Strynadka, N. C. J. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1006067 · Cited by 72
Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
Li, S., McCraw, A. J., Gardner, R. A., Spencer, D. I. R., Karagiannis, S. N., & Wagner, G. K. (2021) · Antibodies · doi:10.3390/antib10040044 · Cited by 30
Self-citationMissing the sweet spot: one of the two N-glycans on human Gb3/CD77 synthase is expendable
Mikolajczyk, K. P., Bereźnicka, A., Szymczak-Kulus, K., Haczkiewicz-Leśniak, K., Szulc, B., Olczak, M., Rossowska, J., Majorczyk, E., Kapczyńska, K., Bovin, N. V., et al. (2021) · Glycobiology · doi:10.1093/glycob/cwab041 · Cited by 14
Kaczmarek, R., Mikołajewicz, K., Szymczak-Kulus, K., Duk, M., Majorczyk, E., Krop‐Watorek, A., Buczkowska, A., & Czerwiński, M. (2016) · Glycoconjugate Journal · doi:10.1007/s10719-016-9716-9 · Cited by 13
Metadata
- Authors
- Wagner, G. K., Pesnot, T., Palcic, M. M., & Jørgensen, R.
- Affiliations
- King's College London (GB)
- University of East Anglia (GB)
- Carlsberg Laboratory (DK)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 290
- Issue
- 52
- Pages
- 31162-31172
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC4692239
- OpenAlex
- W2147769824
- Cited by
- 12
- References
- 45
- Citations by year
- 2023: 2 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2016: 3 · 2015: 1
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1753 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- HZB Repository (Helmholtz-Zentrum Berlin für Materialien und Energie GmbH (HZB)) (submittedVersion, other-oa)
- Funders
- Danmarks Frie Forskningsfond
- Medical Research Council (G0901746)
- Engineering and Physical Sciences Research Council (EP/D059186/1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- UDP-GalNAc, ABO blood group antigens, H antigen, glycosyltransferase inhibitors, enzyme kinetics
- MeSH terms
- ABO Blood-Group System, Humans, Uridine Diphosphate Sugars, Glycosyltransferases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase. https://app.cochat.ai/papers/10.1074/jbc.m115.681262
- The paper
- Wagner, G. K., Pesnot, T., Palcic, M. M., & Jørgensen, R. (2015). Novel UDP-GalNAc Derivative Structures Provide Insight into the Donor Specificity of Human Blood Group Glycosyltransferase. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m115.681262
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.